Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995513 · ClinicalTrials.gov registry record · Phase 4
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 509
- Enrollment target
NCT01995513 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 509 participants.
The verdict
NCT01995513, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 509 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Placebo for Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01995513
The ClinicalTrials.gov registry entry for NCT01995513 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT01995513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01995513 about?
NCT01995513 is a clinical study titled "Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients". The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
What is the current status of trial NCT01995513?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 509 participants. The study started on 2013-10-22. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT01995513?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Placebo for Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT01995513?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.